Tirzepatide vs Pramlintide
It is the weekly shot behind Mounjaro and Zepbound, used for diabetes and weight loss. Large trials show 15% to 21% weight loss. A shot added to mealtime insulin in diabetes. Controlled trials show a small drop in blood sugar and weight, with more nausea and low blood sugar.
Both sit at grade A: strong human evidence. Both are FDA approved.
Evidence
AStrong human evidence
AStrong human evidence
Human studies cited
Animal or cell studies cited
Why the grade
Tirzepatide's weight-loss use rests on the SURMOUNT program of randomized placebo-controlled trials, the largest being SURMOUNT-1 with 2,539 adults, plus trials in type 2 diabetes, sleep apnea, weight maintenance and diabetes prevention. Every approved indication was granted on randomized data, so it grades A.
Approval rested on randomized, placebo-controlled trials in type 1 and type 2 diabetes lasting up to a year; the label summarizes six placebo-controlled trials (four in type 1 and two in type 2 diabetes), the largest with 480 type 1 patients, in which pramlintide lowered HbA1c by about 0.25 to 0.34 percentage points more than placebo and reduced weight. The effect is real but small, and the drug has largely been displaced by GLP-1 agonists.
FDA
FDA approved
Tirzepatide is approved by the FDA as Mounjaro (2022) for type 2 diabetes in adults, extended to children 10 and older and to cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and as Zepbound (2023) for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.
FDA approved
Pramlintide is FDA-approved as Symlin (approved March 2005) for adults with type 1 or type 2 diabetes who use mealtime insulin and have not reached their glucose targets. The label carries a boxed warning about severe hypoglycemia, which is why insulin doses are reduced when it is started.
Sold for
Tirzepatide is the weight-loss injection that outperformed semaglutide, cutting body weight by about a fifth in trials.
Pramlintide is the only approved amylin drug, used as an add-on to mealtime insulin to blunt after-meal glucose spikes and help with weight.
Studies say
Multiple large randomized trials show weight loss of 15 to 21 percent, better glucose control than other diabetes drugs, and improvement in sleep apnea, with weight regain after stopping, which is a clean A.
Randomized trials show pramlintide modestly lowers HbA1c and body weight when added to insulin, at the cost of nausea and a higher risk of insulin-related hypoglycemia, which supports its narrow approved use.
Class
Dual GIP + GLP-1 receptor agonist
Amylin analog
Route
Injection
Injection